QuantumCyte reported an AI-guided digital pathology approach designed to mask healthy tissue on solid tumor biopsies, improving the fraction of tumor DNA available for sequencing. The company described its platform as addressing low-tumor-purity samples that can prevent patients from receiving actionable molecular results. The method identifies tumor borders on biopsy slides and prints a polymer mask to enrich tumor cells before DNA extraction and sequencing. By standardizing tumor purity handling at the physical sampling stage, the approach targets a bottleneck that can silently reduce the clinical utility of genomic testing. For precision oncology labs, the key value is turning sequencing from an assay-limited workflow into a specimen-handling upgrade—potentially lowering the rate of “no-call” or uninformative results due to insufficient tumor content.